Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831623 · ClinicalTrials.gov registry record · NA
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
A NA study of Prostate Cancer, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 167
- Enrollment target
- 1
- Study location
NCT00831623: Completed NA study of Prostate Cancer, sponsored by Loma Linda University.
NCT00831623 is a NA study of Prostate Cancer that has completed, run by Loma Linda University. The registered enrollment target is 167 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00831623, a NA study of Prostate Cancer, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 167 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine hypofractionated conformal proton beam radiation therapy of prostate cancer can achieve similar treatment benefits as our current institutional standard with conventional fractionation.
Primary Outcome
To determine if late CTCAE version 4.0 Grade 3 treatment-related morbidity, which is no worse than that engendered by our current institutional standard with conventional fractionation, can be maintained in a hypofractionated schedule.
Conditions Studied
Interventions
- RADIATION Proton Radiation
- RADIATION Proton
Study Locations (1)
California
- Loma Linda University Medical Center / James M. Slater Proton Treatment Center - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2009-02-17 |
| Est. Completion | 2019-07-18 |
| Phase | NA |
What the finished NCT00831623 record still lists
NCT00831623 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Proton Radiation is the first listed.
NCT00831623 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00831623 about?
NCT00831623 is a clinical study titled "Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer". The purpose of this study is to determine hypofractionated conformal proton beam radiation therapy of prostate cancer can achieve similar treatment benefits as our current institutional standard with conventional fractionation.
What is the current status of trial NCT00831623?
This trial is currently completed. It is a NA study. The enrollment target is 167 participants. The study started on 2009-02-17. Estimated completion is 2019-07-18.
What conditions does trial NCT00831623 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00831623?
The interventions under investigation include: Proton Radiation (RADIATION), Proton (RADIATION).
Who is sponsoring clinical trial NCT00831623?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00831623 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00831623's enrollment target sits among peer trials
167 249th of 735 higher than 486 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI